GLP-1: Glucagon-like peptide-1; RA: receptor agonist. ACS: Acute coronary syndrome; CAD: Coronary artery disease; CHF: Congestive heart failure; CRF: Chronic renal ...

However, a new class of medications, GLP-1 agonists, originally designed for diabetes and obesity management, shows promise as a revolutionary tool in addiction treatment. GLP-1, or glucagon-like ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders. HealthDay News — For people with diabetes, the use of glucagon ...

The analysis included 98,147 GLP-1 RA users and approximately 2.49 million DPP-4i users, with a median follow-up ranging from 1.8 to 3 years. HealthDay News — Glucagon-like peptide 1 receptor ...

If you continue to have this issue please contact [email protected]. GLP-1 receptor agonist use before pregnancy was tied to lower risks for hypertensive disorders of pregnancy and ...

To assess the impact of GLP-1 agonists on incidence and management of adhesive capsulitis, Bergstein and colleagues used the PearlDiver database to perform a retrospective cohort comparison of ...

(Prior studies have simply found a link between taking a GLP-1 receptor agonist and drinking less—but didn’t go so far as to actually prove that the medications caused people to drink less.) ...

Authors say large, multisite study should provide reassurance for short-term risk. (HealthDay News) — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased ...